From heightened demands by regulatory authorities for contextual
demonstration of the benefits and risks of a drug, to the need for
pharmacovigilance to play a more strategic role internally, the
discipline of pharmacovigilance is changing rapidly. In this article,
Marco Anelli at Product Life Group explores that development.